A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy (Tamoxifen/Medroxyprogesterone Acetate) in Women With Advanced, Recurrent, or Persistent Endometria Carcinoma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 May 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; Letrozole (Primary) ; Medroxyprogesterone; Tamoxifen
- Indications Endometrial cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 16 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 13 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.